(Q28218263)

2

0 references

J van Gijn

3

0 references

L J Kappelle

4

0 references

P J Koudstaal

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

5

0 references

language of work or name

English

0 references

publication date

20 May 2006

0 references

published in

The Lancet

0 references

volume

367

0 references

issue

9523

0 references

page(s)

1665-73

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

ESPRIT: protocol change.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Interobserver agreement for the assessment of handicap in stroke patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Interobserver agreement for the assessment of handicap in stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

1 reference

7 January 2021

Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Classification of cause of death after stroke in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Dipyridamole bioavailability in subjects with reduced gastric acidity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Long-term prognosis after lacunar infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Dipyridamole and headache--a pilot study of initial dose titration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021

Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968734-5

7 January 2021